We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Mr. McCaffrey is the President and CEO of Zenith Epigenetics. He is also the Co-Founder, President, & CEO of Resverlogix Corp. (TSX-RVX). He has over 38 years of business experience including 18 years of drug discovery & development.
Don’s expertise in corporate operations has attracted an international team of experts in research, development, and corporate affairs to Zenith & Resverlogix.
As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp. As President and CEO of Zenith, Mr. McCaffrey assembled a world class Oncology team to further the development of this program. In addition to Zenith, Mr. McCaffrey also serves on the Board of Directors of Resverlogix Corp.
Don’s passion lies in supporting non-profit organizations, especially those that support education and the development of future generations of young scientists. Don’s personal donation to the Mount Royal University contributed to the Roderick Mah Centre for Continuous Learning, which supports student facilities within the health and sciences programs. The building is one of North America’s most environmentally sustainable, technologically advanced and designed for learning.
This speaker's sessions: